Drug delivery system for delivery of anti-virals
Described herein is a vaginal ring drug delivery system comprising (i) a core comprising a first thermoplastic polymer and a first therapeutic agent, wherein the first therapeutic agent is dissolved in the first thermoplastic polymer, and (ii) a skin surrounding the core comprising a second thermoplastic polymer and a second therapeutic agent, wherein the second therapeutic agent is in solid form.
1. A vaginal ring drug delivery system comprising (i) a core comprising a first ethylene-vinylacetate copolymer and vicriviroc, wherein the vicriviroc is dissolved in the first ethylene-vinylacetate copolymer, and (ii) a skin surrounding the core comprising a second ethylene-vinylacetate copolymer wherein the second ethylene-vinylacetate copolymer is the only polymer in the skin, and wherein the first ethylene-vinylacetate copolymer has a higher vinylacetate content than the second ethylene-vinylacetate copolymer, and (S)-2-(3-chloro-4-fluorobenzyl)-8-ethyl-10-hydroxy-N,6-dimethyl-1,9-dioxo-1,2,6,7,8,9-hexahydropyrazino [1′,2′:1,5]pyrrolo [2,3-d]pyridazine-4-carboxamide, wherein the (S)-2-(3-chloro-4-fluorobenzyl)-8-ethyl-10-hydroxy-N,6-dimethyl-1,9-dioxo-1,2,6,7,8,9-hexahydropyrazino [1′,2′:1,5]pyrrolo[2,3-d]pyridazine-4-carboxamide is loaded in the skin in solid form, such that a depletion layer is preformed, and upon release, the (S)-2-(3-chloro-4-fluorobenzyl)-8-ethyl-10-hydroxy-N,6-dimethyl-1,9-dioxo-1,2,6,7,8,9-hexahydropyrazino[1′,2′:1,5]pyrrolo [2,3-d]pyridazine-4-carboxamide loaded in the skin displays a near zero order release profile.
2. The drug delivery system of claim 1 , wherein the first ethylene-vinylacetate copolymer has a vinylacetate content of 28% vinylacetate.
3. The drug delivery system of claim 1 , wherein the second ethylene-vinylacetate copolymer has a vinylacetate content of 15% vinylacetate.
4. A vaginal ring drug delivery system comprising (i) a core comprising an ethylene-vinylacetate copolymer having a vinylacetate content of equal to or greater than 28% and vicriviroc, wherein the vicriviroc is in dissolved form, and (ii) a skin surrounding the core, wherein the skin comprises an ethylene-vinylacetate copolymer having a vinylacetate content of less than 28% wherein the ethylene-vinylacetate copolymer having a vinylacetate content of less than 28% is the only polymer in the skin, and (S)-2-(3-chloro-4-fluorobenzyl)-8-ethyl-10-hydroxy-N,6-dimethyl-1,9-dioxo-1,2,6,7,8,9-hexahydropyrazino[1′,2′:1,5]pyrrolo [2,3-d]pyridazine-4-carboxamide, wherein the (S)-2-(3-chloro-4-fluorobenzyl)-8-ethyl-10-hydroxy-N,6-dimethyl-1,9-dioxo-1,2,6,7,8,9-hexahydropyrazino[1′,2′:1,5]pyrrolo [2,3-d]pyridazine-4-carboxamide is loaded in the skin in solid form, such that a depletion layer is preformed, and upon release the (S)-2-(3-chloro-4-fluorobenzyl)-8-ethyl-10-hydroxy-N,6-dimethyl-1,9-dioxo-1,2,6,7,8,9-hexahydropyrazino[1′,2′:1,5]pyrrolo [2,3-d]pyridazine-4-carboxamide loaded in the skin displays a near zero order release profile.
5. The drug delivery system of claim 4 , wherein the ethylene-vinylacetate copolymer in the core has a vinylacetate content between 28-33% vinylacetate.
6. The drug delivery system of claim 4 , wherein the ethylene-vinylacetate copolymer in the core has a vinylacetate content of 28% vinylacetate.
7. The drug delivery system of claim 4 , wherein the ethylene-vinylacetate copolymer in the skin has a vinylacetate content of 15% vinylacetate.